Why did the FDA reject Cingulate’s CTx-1301 ADHD drug application?

The FDA’s Complete Response Letter for Cingulate’s CTx‑1301 focused on manufacturing and Chemistry, Manufacturing, and Controls (CMC) issues rather than safety or efficacy. The company is addressing these process‑related gaps with its manufacturing partner and expects to resubmit once the additional data and inspections are completed.